GEN Reports Positive Phase 2 Trial Results for GN-037 Topical Cream

ANKARA, TURKEY / ACCESSWIRE / September 25, 2024 / GEN Pharmaceuticals, a leading Turkish pharmaceutical company, has announced positive outcomes from its Phase 2 clinical trial evaluating GN-037 topical cream for mild to moderate plaque psoriasis. The results were presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam.

The multicenter, randomized, double-blind, placebo-controlled study included 190 patients across 19 clinical centers in Türkiye. Patients received GN-037, clobetasol 17-propionate, or placebo twice daily for four weeks, followed by four weeks of observation. The study underscored GN-037's efficacy in reducing psoriasis symptoms compared to placebo.

Key findings include a 37.9% treatment success rate at week four for GN-037 patients versus 9.1% for placebo. GN-037 also significantly improved erythema, plaque elevation, and scaling. No new safety concerns were observed.

Abidin Gülmüş, Chairman of GEN, stated, "We are thrilled to announce these positive results, offering new hope for the global psoriasis community." Nadir Ulu, MD, PhD, Vice President of R&D, emphasized GN-037's potential to provide significant improvements for patients with mild to moderate plaque psoriasis.